FDA to Offer Bonus Payments for Speedy Drug Reviews

New pilot program aims to incentivize faster drug approvals, raising concerns about potential impact on safety and ethics.

Published on Feb. 26, 2026

Got story updates? Submit your updates here. ›

The head of the Food and Drug Administration, Marty Makary, plans to start offering bonus payments to agency drug reviewers who complete their work ahead of schedule. The pilot program is intended to 'recognize and reward staff who find ways to be more efficient delivering high-quality work activities that ultimately benefit patients.' However, the announcement raises questions about potential ethical dilemmas if FDA reviewers are seen as being rewarded for rushing steps needed to confirm drug safety and effectiveness.

Why it matters

The FDA's drug review process has long been a point of contention, with critics arguing the agency is too closely aligned with the pharmaceutical industry it regulates. The new bonus program could further erode public trust in the FDA's independence and commitment to rigorous safety standards, especially as the agency has already faced criticism over its handling of vaccines, gene therapies, and other specialty treatments.

The details

Under the pilot program, the first quarterly bonus payments will start going out to FDA employees around August. Payments will be based on 'weighted time savings' achieved by employees and their teams, as well as ratings-based 'work quality and work complexity.' The program is intended to address staffing challenges, as the FDA has lost about 20% of its drug and biologics review staff since President Trump took office due to retirements, resignations, and employees interviewing for jobs in the pharmaceutical industry.

  • The first quarterly bonus payments will start going out to FDA employees around August.
  • The pilot program was announced by FDA Commissioner Marty Makary during a staff presentation on February 26, 2026.

The players

Marty Makary

The commissioner of the Food and Drug Administration who announced the new pilot program to offer bonus payments to agency drug reviewers who complete their work ahead of schedule.

Robert F. Kennedy Jr.

The Health Secretary who has described FDA staffers as 'a sock puppet' of the pharmaceutical industry since becoming the nation's top health official in February of last year.

Dr. Vinay Prasad

The FDA's chief scientist and vaccine director who has personally overruled staff in rejecting a string of experimental therapies and biotech drugs, citing the need for additional studies and more definitive evidence.

Got photos? Submit your photos here. ›

What they’re saying

“'FDA staffers as 'a sock puppet' of industry since becoming the nation's top health official last February.'”

— Robert F. Kennedy Jr., Health Secretary (Associated Press)

What’s next

The FDA will begin rolling out the first quarterly bonus payments to eligible employees around August 2026.

The takeaway

The FDA's new bonus program for speedy drug reviews raises serious concerns about the potential impact on public trust, safety standards, and the agency's independence from the pharmaceutical industry it regulates. As the FDA faces mounting criticism over its handling of vaccines and other specialty treatments, this pilot program could further erode confidence in the agency's commitment to rigorous scientific review.